| Literature DB >> 29512074 |
Silvia Morbelli1,2, Matteo Bauckneht3,4.
Abstract
Amyloid plaques are a neuropathologic hallmark of Alzheimer's disease (AD), which can be imaged through positron emission tomography (PET) technology using radiopharmaceuticals that selectively bind to the fibrillar aggregates of amyloid-β plaques (Amy-PET). Several radiotracers for amyloid PET have been investigated, including 11C-Pittsburgh compound B and the 18F-labeled compounds such as 18F-florbetaben, 18F-florbetapir, and 18F-flutemetamol. Besides the injected radiotracer, images can be interpreted by means of visual/qualitative, semiquantitative, and quantitative criteria. Here we summarize the main differences between the available radiotracers for Amy-PET, the proposed interpretation criteria, and analytical methods.Entities:
Keywords: Alzheimer’s disease; Amyloid PET; Biomarkers; Brain
Mesh：
Substances：
Year: 2018 PMID： 29512074 DOI： 10.1007/978-1-4939-7704-8_13
Source DB: PubMed Journal: Methods Mol Biol ISSN： 1064-3745